Skip to content
For PE-Backed Platforms

One cybersecurity program across the whole platform — and every acquisition.

Valentra Labs runs the cybersecurity program for a PE-backed healthcare platform as one operating layer on Valentra Nexus — rollup due diligence, portfolio-wide standardization, and post-close integration in a single operating record, with a board-ready Decision Packet the sponsor and the platform board can both read.

The rollup inherits the risk

A PE-backed platform inherits a different cybersecurity posture with every acquisition — each acquired practice arrives with its own tools, its own gaps, and its own undocumented risk. Diligence flags the exposure, but post-close it lands on a platform team that has no single operating record, so the same risk is re-discovered at each site and the sponsor sees a portfolio it cannot measure.

Valentra Labs operates one Managed Security Program across the platform and its MSOs. Valentra Nexus standardizes assets, risk, controls, and evidence on a single operating record, folds each acquisition into it through a repeatable post-close integration, and keeps care delivery continuous while it does — producing a board-ready Decision Packet that rolls the platform's risk up portfolio-wide instead of leaving it scattered across acquired entities.

The PE-backed rollup path

The PE / MSO conversion path walks a sponsor and a platform team through how one program is stood up across the portfolio and how each acquisition is folded into it post-close. It is the operating story behind the rollup, end to end.

One Decision Packet, rolled up portfolio-wide

Across the platform and its acquired entities, the program produces a single board-ready Decision Packet — the situation, options, recommendation, evidence, and approval chain — that a sponsor and the platform board read together. It is the same artifact every Valentra Labs program produces, generated by Valentra Nexus.

Decision Packet · v1.0

Q2 2026 — Crown-Jewel Risk Disposition

pkt_2026-04-17_a3f8e1

Situation

Q2 program review covers the crown-jewel ePHI store and its supporting control envelope. 487 endpoints catalogued across three network segments; 12 unsanctioned SaaS surfaces detected by the shadow-IT scan. Continuous monitoring posture is operating; the residual question is risk acceptance for two compensating-control gaps surfaced this cycle.

Risk & Impact

14 critical findings scored against the revenue-at-risk model. Two compensating gaps (vendor-SOC-2 attestation lapse + patch-cycle #38 awaiting CAB sign-off) carry residual risk of $1.4M in unmitigated regulatory exposure if a HITRUST audit lands before remediation closes. Patient-data confidentiality remains the load-bearing impact dimension.

Options

  1. Accept residual risk through Q3, with quarterly board re-review.
  2. Accelerate remediation by re-prioritizing the patch cycle ahead of the planned Q3 platform migration (cost: 2 engineer-weeks).
  3. Transfer risk via expanded cyber-insurance rider (cost: $48K/yr premium delta; coverage gap on ePHI exfiltration remains).

Recommendation

Pursue Option 2 — accelerate remediation. The 2 engineer-weeks of effort cost is recoverable in Q3; the residual exposure is asymmetric (regulatory floor of $1.4M vs. ~$120K labor delta). Document the patch-cycle re-prioritization as a logged decision with the program owner; close the SOC-2 attestation gap via vendor outreach in the same window. Insurance rider deferred to Q4 review.

Evidence

Twelve evidence artifacts back the recommendation — asset inventory, control mapping, vendor SOC-2 status, residual-risk model, patch-cycle telemetry, and the prior packet's audit trail. One control attestation is overridden with a documented compensating-control narrative; two vendor attestations are pending the Q2 refresh window.
ArtifactHashStatusDetailCaptured
Asset inventory snapshot — 487 endpoints#a3f8e1b2verified—
Control mapping cross-walk — 93 controls#b7c4d9e0verified—
Vendor SOC-2 attestation — current#c9d0e2f1pendingRefresh window opens 2026-05-12; vendor confirmed window…
Vendor SOC-2 attestation — secondary processor#d2e3f4a5pending—
Residual-risk model — revenue-at-risk#e1f2a3b4verified—
Patch cycle #38 — CAB queue position#f3a4b5c6overridden—
Overridden per compensating-control narrative — see attached
Penetration test report — Q1 follow-up#a5b6c7d8stale—
Prior packet audit trail — pkt_2026-01-09_b8c4e2#b6c7d8e9verified—

Approval Chain

CIO and CISO have signed. The CCO signature is pending receipt of the vendor-SOC-2 refresh; the program owner has logged the override and the compensating-control narrative.
  1. Chief Information OfficerM. AlvarezSigned 2026-04-17T14:08:11Z
  2. Chief Information Security OfficerJ. ParkSigned 2026-04-17T14:18:42Z
  3. Chief Compliance Officer—Pending signatureAwaiting vendor SOC-2 refresh — window opens 2026-05-12
Generated by Valentra Nexuspkt_2026-04-17_a3f8e1

Aligned to the frameworks you report against

The program maps each operating stage — asset, risk, control, evidence, work, decision — to the frameworks healthcare cybersecurity teams report against, so a standardized risk posture rolls up consistently across every acquired entity. Valentra Nexus carries the full framework-alignment grid; see how the stages line up on the platform page.

See the framework alignment on Valentra Nexus

Strategy Call See Valentra Nexus

Valentra Labs runs one Managed Security Program across a PE-backed healthcare platform and its acquired practices on Valentra Nexus — shared assets, risk, controls, and evidence — and produces a board-ready Decision Packet that rolls up portfolio-wide, from diligence to post-close.

as of